Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
- DOI
- 10.1016/s2213-8587(25)00052-x
- Published
- 2025-07
- Container
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-25-00052-x,
title = {Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial},
author = {Liana K Billings and Francesco Andreozzi and Marie Frederiksen and Pierre Gourdy and Amoolya Gowda and Linong Ji and Laura Pletsch-Borba and Ryo Suzuki and A G Unnikrishnan and André G D Vianna},
year = {2025},
journal = {The Lancet Diabetes \& Endocrinology},
doi = {10.1016/s2213-8587(25)00052-x},
url = {https://doi.org/10.1016/s2213-8587(25)00052-x}
}RIS
TY - JOUR TI - Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial AU - Liana K Billings AU - Francesco Andreozzi AU - Marie Frederiksen AU - Pierre Gourdy AU - Amoolya Gowda AU - Linong Ji AU - Laura Pletsch-Borba AU - Ryo Suzuki AU - A G Unnikrishnan AU - André G D Vianna PY - 2025 JO - The Lancet Diabetes & Endocrinology DO - 10.1016/s2213-8587(25)00052-x UR - https://doi.org/10.1016/s2213-8587(25)00052-x ER -
APA
Billings, L. K., Andreozzi, F., Frederiksen, M., Gourdy, P., Gowda, A., Ji, L., Pletsch-Borba, L., Suzuki, R., Unnikrishnan, A. G., & Vianna, A. G. D. (2025). Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(25)00052-x
Source records
- crossref · retrieved 2026-09-27T11:28:09.188Z